Use of perforin-deficient pfpCTLs and Fas-resistant CT26 tumor cells will eliminate the function of perforin and Fas/FasL effector mechanisms of the CTLs, thus reducing the CTL cytotoxicity background for optimal TRAIL function evaluation. The gene discussed is FAS; the disease is neoplasm.